Elamipretide, a mitochondria-targeted peptide, restored oocyte quality and increased litter size in aged mice, with parallel improvements in the maturation, fertilization, and cleavage of aged human oocytes. The effect was traced to coordinated nuclear and cytoplasmic maturation driven by a vitamin B6–VEGF signaling axis, alongside improved mitochondrial metabolism and organelle reorganization. Ovarian aging, long considered largely irreversible, appears partially tractable through targeted mitochondrial support.
Key Points
- Elamipretide increased litter size and oocyte quality in aged mice
- Aged human oocytes showed improved maturation, fertilization, and cleavage rates
- Vitamin B6–VEGF axis drove nuclear and cytoplasmic maturation recovery
Longevity Analysis
Ovarian decline is among the earliest and steepest age-related losses in human physiology, making the oocyte a sensitive readout of mitochondrial integrity well before other tissues show measurable failure. Restoring energy production and cytoskeletal organization within a single cell type produced functional reproductive outcomes across three species, which argues that declining fertility reflects correctable metabolic interference rather than fixed cellular exhaustion. The vitamin B6 dependency is notable: a micronutrient cofactor sitting upstream of a vascular signaling pathway that governs tissue renewal, linking nutritional status directly to regenerative capacity.
Original published by Wiley Aging Cell, by Hao‐Lin Zhang, Yue Wang, Caizhu Wang, Xin Guo, Huanhua Chen, Yu‐Xuan Hou, Xuan Wu, Zi‐Jian Wu, Wen‐Lin Pan, Rui‐Jie Ma, Ping‐Shuang Lu, Jinhui Shu, Shao‐Chen Sun .